Société Générale — M&A Activity 2020

May 11, 2020

National Storage Mechanism | Additional information

RNS Number : 3466M

Societe Generale SA

08 May 2020

Ap19

FORM 8.3

IRISH TAKEOVER PANEL

DISCLOSURE UNDER RULE 8.3 OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

DEALINGS BY PERSONS WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

1.       KEY INFORMATION

Name of person dealing (Note 1)	Société Générale S.A.
Company dealt in	Willis Towers Watson plc
Class of relevant security to which the dealings being disclosed relate (Note 2)	US$0.000304635 ordinary shares
Date of dealing	07/05/2020

2.         INTERESTS AND SHORT POSITIONS

(a)        Interests and short positions (following dealing) in the class of relevant security dealt in (Note 3)

	Long		Short
Number	(%)	Number	(%)
(1) Relevant securities	102,438	0.08	7,358	0.01
(2) Derivatives (other than options)	88	0.00	14,618	0.01
(3) Options and agreements to purchase/sell	0	0.00	0	0.00
Total	*1,385,000	*1.08	21,976	0.02

* Include the holding of 1,282,474 shares on borrow products

(b)        Interests and short positions in relevant securities of the company, other than the class dealt in (Note 3)

Class of relevant security:	Long		Short
	Number	(%)	Number	(%)
(1) Relevant securities
(2) Derivatives (other than options)
(3) Options and agreements to purchase/sell
Total

Ap20

1.       DEALINGS (Note 4)

(a)      Purchases and sales

Purchase/sale	Number of relevant securities	Price per unit USD (Note 5)
Purchase	100	192.2
Purchase	300	193.15
Purchase	2,259	193.15
Sale	100	189.83
Sale	100	191.66
Sale	100	192.69
Sale	4	192.71
Sale	65	192.71
Sale	1	192.63
Sale	100	193.15
Sale	40	192.34
Sale	60	192.34
Sale	10	191.46
Sale	40	191.46
Sale	50	191.46
Sale	93	191.46
Sale	7	191.46
Sale	66	192.94
Sale	18	192.94
Sale	16	192.94
Sale	7	191.93
Sale	93	191.93
Sale	48	193.01
Sale	52	193.01
Sale	100	193.22
Sale	100	191.91
Sale	8	192.91
Sale	92	192.91
Sale	65	192.78
Sale	35	192.78
Sale	100	190.48
Sale	4	191.33
Sale	4	191.33
Sale	42	191.33
Sale	13	191.33
Sale	95	193.13
Sale	5	193.13
Sale	5	193.14
Sale	95	193.14
Sale	4	192.405
Sale	96	192.35
Sale	100	192.97
Sale	50	189.84
Sale	50	189.84
Sale	100	191.42
Sale	100	191.68
Total Purchases	2,659
Total Sales	2,333

(b)      Derivatives transactions (other than options transactions)

Product name, e.g. CFD	Nature of transaction (Note 6)	Number of relevant securities (Note 7)	Price per unit USD (Note 5)

(c)      Options transactions in respect of existing relevant securities

(i)       Writing, selling, purchasing or varying

Product name, e.g. call option	Writing, selling, purchasing, varying etc.	Number of securities to which the option relates (Note 7)	Exercise price	Type, e.g. American, European etc.	Expiry date	Option money paid/received per unit (Note 5)

(ii)      Exercising

Product name, e.g. call option	Number of securities	Exercise price per unit (Note 5)

(d)      Other dealings (including transactions in respect of new securities) (Note 4)

Nature of transaction (Note 8)	Details	Price per unit (if applicable) (Note 5)

Ap21

2.       OTHER INFORMATION

Agreements, arrangements or understandings relating to options or derivatives

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

Is a Supplemental Form 8 attached? (Note 9)                                            No

Date of disclosure	08/05/2020
Contact name	Société Générale - Disclosure team
Telephone number	+33 1 42 14 92 74
If a connected EFM, name of offeree/offeror with which connected
If a connected EFM, state nature of connection (Note 10)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

ISEFIFIEEFITIII